Chengdu Easton Biopharmaceuticals Co., Ltd

Chengdu Easton Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd.

Yongzhe Xiang

Ying Wang

Guodong Cen

Long Huang

Jian Ming Liu

Jibing Zhang

Ning Zhou

Haitao Yang

Qing Dong

Yang Liu

Jian Liu

Jianguo Li

Jianjing Jia

Qiangqiang Liu

Hui Qiao

Provided a complex of formula is [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3'-methyl-2&#x2032;-(pentanoyl {2&#x2033;-(tetrazol-5-ylate) biphenyl-4&#x2032;-ylmethyl}amino) butyrate].XCa.YNa.ZHO, wherein X=1-3, Y=12-16, Z=9-18, and 2X+Y=18, and represented by formula (I). Also disclosed are the method of preparing the complex and the method of treating chronic heart disease using a medicament comprising the complex. 

Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor

The present invention relates to the field of pharmaceutical chemistry, specifically to a class of compounds containing lactam and derivative thereof, and especially to a pyridine derivative as shown in general formula (I), preparation method and the use thereof as a Factor Xa inhibitor. The present invention further relates to the medical use of the compound and derivative thereof in preparation of anticoagulant drugs, particularly to the use in preparation of drugs for preventing or treating thrombosis or embolism. 

Pyridine derivative and medical use thereof

The present invention discloses a xanthine derivative having the structure of the following general formula (I) or a pharmaceutically acceptable salt thereof; further discloses a preparation method for the xanthine derivative or a pharmaceutically acceptable salt thereof; and further discloses the use of the xanthine derivative or a pharmaceutically acceptable salt thereof. Through experiments of DPP-IV activity inhibition experiments in vitro, impact on glucose tolerance in normal mice and impact on blood glucose in spontaneous diabetic mice, it proves that the compounds and pharmaceutically acceptable salts thereof show good DPP-IV inhibition activity, can be applied to prepare medicines for treating dipeptidyl peptidase IV-related diseases, and more particularly, can be applied to the use of medicines for treating type II diabetes or diseases of abnormal glucose tolerance. 

Xanthine derivative

Growing community of inventors

Chengdu, China

Yongzhe Xiang